The UK Medicines and Healthcare products Regulatory Agency has published detailed guidance on what its planned international recognition procedure (IRP) will require of companies who wish to use the route to submit their drug marketing applications when it is launched next year.
The agency is also seeking feedback to help shape the approach it will use to end the European Commission Decision Reliance Procedure (ECDRP) that it introduced in January 2021 as a temporary
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?